(Q37848666)

24 August 2017

1 reference

title

Targeted therapy in GIST: in silico modeling for prediction of resistance (English)

1 reference

24 August 2017

1 reference

1

1 reference

24 August 2017

Tiziana Negri

3

0 references

Elena Tamborini

object named as

Elena Tamborini

series ordinal

2

0 references

Sabrina Pricl

object named as

Sabrina Pricl

series ordinal

4

0 references

Silvana Pilotti

series ordinal

5

object named as

Silvana Pilotti

1 reference

24 August 2017

language of work or name

English

0 references

publication date

1 March 2011

1 reference

Nature Reviews Clinical Oncology

24 August 2017

published in

1 reference

24 August 2017

volume

8

1 reference

24 August 2017

issue

3

1 reference

24 August 2017

page(s)

161-170

1 reference

Diverse somatic mutation patterns and pathway alterations in human cancers

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.3

Targeted therapies: the rare cancer paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.3

Tyrosine kinase inhibition: Ligand binding and conformational change in c-Kit and c-Abl

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.3

Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.3

Kinase domain mutations in cancer: implications for small molecule drug design strategies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.3

Switch control pocket inhibitors of p38-MAP kinase. Durable type II inhibitors that do not require binding into the canonical ATP hinge region

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.3

Biochemical and biophysical characterization of unique switch pocket inhibitors of p38α.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.3

Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.3

Clinicopathologic profile of gastrointestinal stromal tumors (GISTs) with primary KIT exon 13 or exon 17 mutations: a multicenter study on 54 cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.3

Biology of gastrointestinal stromal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.3

Activate and resist: L576P-KIT in GIST.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.3

Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.3

Prognostic stratification of high-risk gastrointestinal stromal tumors in the era of targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.3

Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.3

A molecular portrait of gastrointestinal stromal tumors: an integrative analysis of gene expression profiling and high-resolution genomic copy number

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.3

Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.3

KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.3

Ras, PI(3)K and mTOR signalling controls tumour cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.3

Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.3

Molecular pathogenesis of multiple gastrointestinal stromal tumors in NF1 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.3

A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.3

c-Kit/PDGFRA gene status alterations possibly related to primary imatinib resistance in gastrointestinal stromal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.3

Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.3

Heterogeneity of kinase inhibitor resistance mechanisms in GIST

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.3

Rhabdomyosarcomatous differentiation in gastrointestinal stromal tumors after tyrosine kinase inhibitor therapy: a novel form of tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.3

Molecular basis of the constitutive activity and STI571 resistance of Asp816Val mutant KIT receptor tyrosine kinase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.3

Imatinib response in two GIST patients carrying two hitherto functionally uncharacterized PDGFRA mutations: an imaging, biochemical and molecular modeling study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.3

T670X KIT mutations in gastrointestinal stromal tumors: making sense of missense

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.3

Sequence and structure signatures of cancer mutation hotspots in protein kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.3

Sunitinib-resistant gastrointestinal stromal tumors harbor cis-mutations in the activation loop of the KIT gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.3

KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.3

Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.3

Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.3

Exploiting the promiscuity of imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.3

Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.3

Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRAD842V mutation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.3

Protein kinase C-theta regulates KIT expression and proliferation in gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.3

Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.3

Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.3

Inhibitors of deacetylases suppress oncogenic KIT signaling, acetylate HSP90, and induce apoptosis in gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.3

Proapoptotic activity of bortezomib in gastrointestinal stromal tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.3

A phase I-II study of everolimus (RAD001) in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.3

Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.3

Double resistance to imatinib and AMG 706 caused by multiple acquired KIT exon 17 mutations in a gastrointestinal stromal tumour

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.3

Secondary mutations in the kinase domain of the KIT gene are predominant in imatinib-resistant gastrointestinal stromal tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.3

Even better kinase inhibitors for chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.3

Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.3

PDGFRA activating mutations in gastrointestinal stromal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.3

Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.3

Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.3

Clinical and molecular genetics of patients with the Carney-Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.3

Molecular analysis of secondary kinase mutations in imatinib-resistant gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.3

Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.3

Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.3

Functional analyses and molecular modeling of two c-Kit mutations responsible for imatinib secondary resistance in GIST patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.3

Targeting tyrosine kinases in cancer: the second wave

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.3

Resistance to c-KIT kinase inhibitors conferred by V654A mutation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.3

Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.3

31 March 2020

Identifiers

DOI

10.1038/NRCLINONC.2011.3

1 reference

24 August 2017

1 reference